December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcus Biosciences, Inc. Common Stock (NY:RCUS)

22.17 -0.42 (-1.86%)
Streaming Delayed Price Updated: 12:18 PM EDT, Mar 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arcus Biosciences, Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Arcus (RCUS) Q4 2025 Earnings Call Transcript ↗
Arcus (RCUS) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Arcus Biosciences Inc (NYSE:RCUS) Reports Mixed Q4 2025 Results as Pipeline Strategy Pivots to Casdatifan ↗
Via Chartmill
News headline image
Arcus Biosciences President Sells $2 Million as Stock Delivers 48% Annual Return ↗
Arcus Biosciences, a clinical-stage oncology innovator, reported significant insider selling as its stock capped a strong one-year return. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why Did Arcus Biosciences Stock Slump 10% Today? ↗
Arcus will stop testing a domvanalimab-based drug combination in upper gastrointestinal cancers after independent reviewers found the treatment did not improve survival. 
Via Stocktwits
News headline image
Analyst Expectations For Arcus Biosciences's Future ↗
 
Via Benzinga
Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’ ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
What to Expect from Arcus Biosciences's Earnings ↗
 
Via Benzinga
News headline image
Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan ↗
Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months ↗
Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab combination therapy. 
Via Benzinga
News headline image
How Arcus Biosciences Aims To Take On Merck In Cancer Treatment ↗
Shares climbed Tuesday as enthusiasm grows for the biotech company's experimental cancer drug. 
Via Investor's Business Daily
News headline image
Why Is Arcus Biosciences Stock Trading Higher On Monday? ↗
Arcus Biosciences reports casdatifan monotherapy data in renal cancer, showing a 35% response rate and median progression-free survival not yet reached. 
Via Benzinga
News headline image
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 25, 2025 ↗
 
Via Benzinga
News headline image
Expert Outlook: Arcus Biosciences Through The Eyes Of 8 Analysts ↗
 
Via Benzinga
News headline image
Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus ↗
On CNBC's Mad Money Lightning Round, Jim Cramer endorsed buying Uranium Energy and called Arcus Biosciences a speculative play. 
Via Benzinga
News headline image
Gilead Lifts Annual Outlook As Yeztugo Launch Nears ↗
Gilead raised its 2025 earnings and sales outlook after posting better-than-expected Q2 results, led by strong HIV and oncology drug sales. 
Via Benzinga
News headline image
Arcus (RCUS) Q2 Revenue Jumps 310% ↗
Via The Motley Fool
News headline image
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Unveiling 5 Analyst Insights On Arcus Biosciences ↗
 
Via Benzinga
News headline image
Where Arcus Biosciences Stands With Analysts ↗
 
Via Benzinga
News headline image
Demystifying Arcus Biosciences: Insights From 4 Analyst Reviews ↗
 
Via Benzinga
News headline image
Why ThredUp Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Forecasting The Future: 5 Analyst Projections For Arcus Biosciences ↗
 
Via Benzinga
News headline image
Arcus Biosciences Shares Are Down Today: What's Going On? ↗
Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock offering. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Ericsson Posts Weak Results, Joins East West Bancorp And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.